- AGC Pharma Chemicals was named Best in Class in four Small/Mid‑Sized Small Molecule API CDMO categories, its second consecutive year receiving the recognition.
- The awards were co‑hosted by Outsourced Pharma and Life Science Connect and based on client evaluations with analysis and validation by Tufts CSDD.
- The Small/Mid‑Sized Small Molecule API segment is defined as CDMO companies with annual CDMO revenues below USD 1 billion.
- AGC offers cGMP CDMO services across Japan, the United States and Europe and covers small‑molecule APIs, agrochemicals, biopharmaceuticals, and gene and cell therapies.
Award recognition
AGC Pharma Chemicals was named “Best in Class” in four categories within the Small/Mid‑Sized Small Molecule API CDMO segment at the CDMO Leadership Awards 2026, marking its second consecutive year receiving the recognition.
Selection process
The awards were co‑hosted by Outsourced Pharma and Life Science Connect; recipients were identified from evaluations by pharmaceutical and biopharmaceutical clients who worked with CDMOs in the prior two years, with analysis and validation by the independent Tufts Center for the Study of Drug Development (Tufts CSDD).
Evaluation scope
CDMOs were assessed across the full lifecycle of outsourced development and manufacturing projects, covering technical capabilities as well as project management, team structure, and collaboration with client companies.
Recognized strengths
AGC’s highlighted strengths were: highly specialized and responsive staff enabled by a collaborative team structure (Overall Staff); transparent, closely collaborative client relationships (Cultural Fit); effective use of advanced technologies and systems to improve execution and operational efficiency (Technology Use); and flexible support for transitions from development to commercial scale and capacity expansion (Scaling Support).
Service footprint
AGC provides cGMP CDMO services across Japan, the United States and Europe and supports modalities including small‑molecule APIs, agrochemicals, biopharmaceuticals, and gene and cell therapies; the Small/Mid‑Sized Small Molecule API segment refers to CDMOs with annual CDMO revenues below USD 1 billion.
